RAC race oncology ltd

2.11%

$1.16

Does this also mean that RAC itself might now be unable to get...

First 6 Last

Share
Profile

Follow
IndexInvestor

9,053 Posts.

1473

07/07/24

14:55

Post #: 74643192
Share

Originally posted by RaceOncology: ↑

A very good question. While bisantrene the molecule is out of patent, our new RC220 formulation (i.e. the drug product) is not. What we have been able to do is reformulate bisantrene so that the problem of crystallisation in the blood that caused it to be abandoned by the original developer (Lederle), has been solved.

This process is very similar to what Abraxis did with Taxol to create Abraxane - they reformulated Taxol to solve the solubility issues with the original formulation and went on to sell billion of dollars worth of Abraxane over the past couple of decades. Reformulation to solve drug problems can be very profitable if done intelligently. Here is a link to some of the history of Abraxane.

https://stabiopharma.com/where-it-all-began-how-007-became-abraxane/

The obvious follow up question is won't someone just start selling the old formulation once our new formulation of bisantrene is approved? The answer is no for two reasons:

1. The old formulation is not FDA or EMA approved. Any developer of the old formulation would have to spend tens of millions dollars to bring the old formulation to market, but as soon as they brought it to market the generic drug manufacturers could start selling the own version of the old formulation and the price would immediately fall to that of a generic drug. No company will invest all the money required to develop the original formulation of bisantrene if they will face immediate generic competition.

2. Even if some company is crazy enough to spend all the money required to get the old formulation of bisantrene approved, no doctors or patients are going to participate in any of the trials need for approval. You can’t run a clinical trial of a worse version of an approved drug that offers no benefit to the patient - it would be unlikely that you could even get ethics approval to run such a trial.

This same priniciple applies to a different formulation of bisantrene. Unless this new formulation offered some significant clinical benefit over our RC220 formulation then it can’t be trialed and hence approved. This is exactly what happened with Abraxane which did not face any direct competition until the original formulation patents ended and the generic manufacturers could start making it.

Expand

Does this also mean that RAC itself might now be unable to get ethics approval to run a RC110 trial (not that RAC is planning to do so)?

Last edited by IndexInvestor: 07/07/24

RAC Price at posting: $1.70 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

THL

Tourism Holdings says Liberation Day tariffs smashed US RV demand

Trump chides Powell as Goldman call for calm. The RBA must be nervous

NMG

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

I88

Infini Resources onto Phase 2 at Portland Creek after spotting 'widespread uranium'

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

There are more pages in this discussion • 38 more messages in this thread...

First 6 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.16		Change -0.025(2.11%)		Mkt cap ! $201.5M

Open	High	Low	Value	Volume
$1.22	$1.22	$1.16	$42.21K	35.95K

Buyers (Bids)

No.	Vol.	Price($)
3	1942	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.18	542	1

View Market Depth

No.	Vol.	Price($)
2	1934	1.155
4	5363	1.150
1	600	1.145
3	9368	1.140
4	12910	1.130

Price($)	Vol.	No.
1.175	542	1
1.185	542	1
1.200	16871	3
1.205	2500	1
1.220	21445	4

Last trade - 11.46am 04/07/2025 (20 minute delay)

RAC (ASX) Chart

Does this also mean that RAC itself might now be unable to get...

Tourism Holdings says Liberation Day tariffs smashed US RV demand

Trump chides Powell as Goldman call for calm. The RBA must be nervous

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

Infini Resources onto Phase 2 at Portland Creek after spotting 'widespread uranium'

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Does this also mean that RAC itself might now be unable to get...

Top Stories

Tourism Holdings says Liberation Day tariffs smashed US RV demand

Trump chides Powell as Goldman call for calm. The RBA must be nervous

New Murchison Gold blasts off at Crown Prince as 'better than expected' results return

Infini Resources onto Phase 2 at Portland Creek after spotting 'widespread uranium'

Listen: HotCopper Wire Podcast 016 – FY25 ended up not so bad... but Trump unpause is coming

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News